Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index; none of the 3 sources its claims cite is checked for support yet.
Abstract
Objective: This report presents a cross-sectional analysis of the baseline characteristics of subjects with Leber hereditary optic neuropathy enrolled in the gene therapy trials RESCUE and REVERSE, to illustrate the evolution of visual parameters over the first year after vision loss. Methods: RESCUE and REVERSE were 2 phase III clinical trials designed to assess the efficacy of rAAV2/2-ND4 gene therapy in ND4-LHON subjects. At enrollment, subjects had vision loss for ≤6 months in RESCUE, and between 6 and 12 months in REVERSE. Functional visual parameters (best-corrected visual acuity [BCVA], contrast sensitivity [CS], and Humphrey Visual Field [HVF]) and structural parameters assessed by spectral-domain optical coherence tomography were analyzed in both cohorts before treatment. The cross-sectional analysis of functional and anatomic parameters included the baseline values collected in all eyes at 2 different visits (Screening and Inclusion). Results: Seventy-six subjects were included in total, 39 in RESCUE and 37 in REVERSE. Mean BCVA was significantly worse in RESCUE subjects compared with REVERSE subjects (1.29 and 1.61 LogMAR respectively, P = 0.0029). Similarly, mean CS and HVF were significantly more impaired in REVERSE vs RESCUE subjects (P < 0.005). The cross-sectional analysis showed that the monthly decrease in BCVA, ganglion cell layer macular volume, and retinal nerve fiber layer thickness was much more pronounced in the first 6 months after onset (+0.24 LogMAR, −0.06 mm 3, and −6.00 μm respectively) than between 6 and 12 months after onset (+0.02 LogMAR, −0.01 mm 3, and −0.43 μm respectively). Conclusion: LHON progresses rapidly in the first months following onset during the subacute phase, followed by relative stabilization during the dynamic phase.
Overview
CoChat Summary
TL;DR
This cross-sectional baseline analysis of the RESCUE and REVERSE phase III gene therapy trials describes visual function and retinal anatomy in 76 subjects with m.11778G>A LHON during the first year after vision loss. Functional and structural parameters worsened most rapidly in the first 6–8 months after onset, then relatively stabilized.
Key findings
- Among 76 subjects (39 RESCUE, 37 REVERSE), mean duration of vision loss was 112.1 days in RESCUE vs 271.0 days in REVERSE (P < 0.0001). Baseline BCVA was worse in REVERSE than RESCUE (1.61 vs 1.29 LogMAR, P = 0.0029), as were contrast sensitivity (0.30 vs 0.62 LogCS, P = 0.0031) and HVF mean deviation (−29.0 vs −19.9 dB, P = 0.0039).
- Structural loss was also more advanced in REVERSE: GCL macular volume 0.53 vs 0.73 mm³, RNFL temporal quadrant 28.2 vs 49.6 μm, and average RNFL 69.7 vs 99.1 μm (all P < 0.0001).
- Estimated monthly rates in the first 6 months after onset were +0.24 LogMAR for BCVA, −0.06 mm³ for GCL macular volume, and −6.00 μm for RNFL temporal quadrant thickness; between 6 and 12 months, the corresponding rates were +0.02 LogMAR, −0.01 mm³, and −0.43 μm.
- Four RESCUE eyes had normal BCVA at enrollment but already showed contrast sensitivity below 1.8 LogCS and presymptomatic increases in retinal layer thickness/volume.
Methods
- Cross-sectional analysis of baseline data from RESCUE (NCT02652767) and REVERSE (NCT02652780), two randomized, double-masked, sham-controlled phase III trials of rAAV2/2-ND4 in subjects with m.11778G>A LHON; RESCUE enrolled vision loss ≤180 days and REVERSE 181–365 days, with subjects at least 15 years old and vision of count fingers or better in both eyes.
- Functional measures included ETDRS BCVA, Pelli–Robson contrast sensitivity, and Humphrey Visual Field 30-2; structural measures included SD-OCT GCL and RNFL parameters. Functional baseline was the last pre-treatment assessment; OCT baseline averaged screening and inclusion visits.
- Analyses used mixed-effects ANOVA for dependent data, linear regression on individual data points to estimate monthly rates of change, and LOESS nonparametric regression; SAS version 9.4 was used.
Limitations
- Stated: the analysis is cross-sectional, subjects were subsequently treated with gene therapy and not followed longitudinally as untreated individuals, so the reconstruction of natural history is not based on prospective follow-up of individual patients. Also stated: only reliable HVF tests were included, excluding more than half of the data; whole mitochondrial genome sequencing was not performed and nuclear genome sequencing was not specifically requested to exclude other optic atrophy genes; onset of vision loss was based on patient testimony.
- Evident from the text: the two cohorts differ by design in duration of vision loss, so baseline comparisons between RESCUE and REVERSE are confounded by disease stage. The cross-sectional design cannot establish individual trajectories or causality, and the absence of an untreated longitudinal control limits natural-history inference.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
0 Valid · 0 Not valid · 2 Not checked · 47 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cross-sectional CS values declined similarly as BCVA measures in the first 8 months (∼250 days) of vision loss”
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > RESULTS > Contrast Sensitivity
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the mean duration of vision loss was shorter in RESCUE (3.7 months/112.1 days) than in REVERSE (8.9 months/271.0 days) (Table 1). This difference was statistically significant (P < 0.0001).”
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > RESULTS > Duration of Vision Loss
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In RESCUE, all eyes were on-chart for CS at inclusion.”
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > RESULTS > Contrast Sensitivity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“mean CS and HVF were significantly more impaired in REVERSE vs RESCUE subjects (P < 0.005).”
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > Abstract > Results:
plainstates an associationn = 6 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar to BCVA and CS, cross-sectional HVF MD values substantially worsened in the first 8 months (∼250 days) after onset of vision loss.”
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > RESULTS > Mean Deviation of HVF
plainstates an associationn = 110- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
15 more claims
Create a free account to see all 49 claims and to verify the 3 references still open.
- Probably not a substantial claim. 15
- It may state two separate claims as one. 16
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It is also the first clinical study assessing the efficacy of a bilateral IVT of lenadogene nolparvovec, while in the three previous clinical studies REVEAL,21 REVERSE16–18 and RESCUE,17–19 lenadogene nolparvovec was exclusively administered as unilateral IVT.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > Abstract > Conclusion:
“REVERSE (NCT02652780)”
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > METHODS > Study Design
“RESCUE and REVERSE (ClinicalTrial.gov NCT02652767 and NCT026527080)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > CONCLUSION
“Based on protocol inclusion criteria, only the average duration of vision loss at enrollment was significantly different between studies.”
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > RESULTS > Demographic Characteristics
“N subjects (%) | 26 (34.2%) | 19 (48.7%) | 7 (18.9%) | 0.0062”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > RESULTS > Retinal Anatomy: SD-OCT Assessment
“the average RNFL thickness in the temporal quadrant was 28.2 μm vs 49.6 μm, respectively.”
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > RESULTS > Demographic Characteristics
“Mean (SD) | 39.2 (19.2) | 49.6 (20.9) | 28.2 (8.0) | <0.0001”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > Abstract > Results:
“Mean BCVA was significantly worse in RESCUE subjects compared with REVERSE subjects (1.29 and 1.61 LogMAR respectively, P = 0.0029).”
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > RESULTS > Visual Function: BCVA, CS, and HVF
“At baseline, BCVA was on average more preserved in RESCUE subjects compared with REVERSE subjects, a difference that was statistically significant (1.29 LogMAR [20/400 Snellen] and 1.61 LogMAR [20/800 Snellen] respectively, P = 0.0029)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > RESULTS > Visual Function: BCVA, CS, and HVF
“95% CI | −0.073 to −0.032 | −0.197 to 0.111 | −0.014 to 0.034”
§ Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies > RESULTS > Visual Function: BCVA, CS, and HVF
“P-value | <0.0001 | <0.0001 | 0.4235”
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy
Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., & Nikoskelainen, E. K. (1988) · Science · doi:10.1126/science.3201231 · Cited by 2,440
THE DESIGN OF A NEW LETTER CHART FOR MEASURING CONTRAST SENSITIVITY
Pelli, D. G., Robson, J. G., & Wilkins, A. J. (1988) · Cited by 1,308
Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies
Yu-Wai-Man, P., Griffiths, P. G., & Chinnery, P. F. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.002 · Cited by 633 · cited 1×
“L eber hereditary optic neuropathy (LHON) is a maternally inherited blinding bilateral optic neuropathy caused by mitochondrial DNA (mtDNA) missense point mutations affecting complex I in the mitochondrial respiratory chain (1,2), resulting in selective dysfunction and subsequent apoptotic loss of retinal ganglion cel…”
Self-citationThe Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Man, P. Y. W., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 483
Self-citationNewman, N. J., Lott, M. T., & Wallace, D. C. (1991) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)76784-4 · Cited by 403 · cited 1×
“However, it should be noted that many patients in the acute phase of LHON may not have visible or demonstrable RNFL thickening (6), and, conversely, the presence of transient RNFL thickening in asymptomatic carriers who never proceed to symptomatic visual loss makes it difficult to use anatomic or functional measures…”
Self-citationNormal values for the Pelli-Robson contrast sensitivity test
Mäntyjärvi, M., & Laitinen, T. (2001) · Journal of Cataract and Refractive Surgery · doi:10.1016/s0886-3350(00)00562-9 · Cited by 259
BARBONI, P., SAVINI, G., VALENTINO, M., MONTAGNA, P., CORTELLI, P., DENEGRI, A., SADUN, F., BIANCHI, S., LONGANESI, L., & ZANINI, M. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2004.06.034 · Cited by 247
Self-citationYu-Wai-Man, P., Newman, N. J., Carelli, V., Moster, M. L., Biousse, V., Sadun, A. A., Klopstock, T., Vignal-Clermont, C., Sergott, R. C., Rudolph, G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz7423 · Cited by 232
Self-citationCarelli, V., Carbonelli, M., de Coo, I. F., Kawasaki, A., Klopstock, T., Lagrèze, W. A., La Morgia, C., Newman, N. J., Orssaud, C., Pott, J. W. R., et al. (2017) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000570 · Cited by 228
Self-citationEllouze, S., Augustin, S., Bouaita, A., Bonnet, C., Simonutti, M., Forster, V., Picaud, S., Sahel, J.-A., & Corral-Debrinski, M. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.08.013 · Cited by 222
Self-citation
Cited by
Newman, N. J., Yu-Wai-Man, P., Biousse, V., & Carelli, V. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00174-0 · Cited by 97
Self-citationRandomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy
Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A.-G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., et al. (2023) · Brain · doi:10.1093/brain/awac421 · Cited by 87
Self-citationMusiani, F., Rigobello, L., Iommarini, L., Carelli, V., Esposti, M. D., & Ghelli, A. M. (2022) · Molecules · doi:10.3390/molecules27041341 · Cited by 11
Self-citationLeber Hereditary Optic Neuropathy: Molecular Pathophysiology and Updates on Gene Therapy
Chi, S.-C., Cheng, H., & Wang, A.-G. (2022) · Biomedicines · doi:10.3390/biomedicines10081930 · Cited by 8
Study design and baseline characteristics for the reflect gene therapy trial ofm.11778g>A/ND4-LHON
Subramanian, P. S., Newman, N. J., Moster, M. L., Wang, A.-G., Yu‐Wai‐Man, P., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal‐Clermont, C., et al. (2022) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2022-001158 · Cited by 4
Self-citation
Metadata
- Authors
- Moster, M. L., Sergott, R. C., Newman, N. J., Yu-Wai-Man, P., Carelli, V., Bryan, M. S., Smits, G., Biousse, V., Vignal-Clermont, C., Klopstock, T., Sadun, A. A., DeBusk, A. A., Carbonelli, M., Hage, R., Priglinger, S., Karanjia, R., Blouin, L., Taiel, M., Katz, B., Sahel, J. A., & for the LHON study group
- Affiliations
- Thomas Jefferson University (US)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Moster, Mark L.
- ORCID
- Venue
- Journal of Neuro-Ophthalmology
- Published
- 2021-07-23
- Volume
- 41
- Issue
- 3
- Pages
- 298-308
- ISSN
- 1070-8022 (ISSN-L)
- PMC
- PMC8366757
- OpenAlex
- W3183408771
- Cited by
- 7
- References
- 30
- Citations by year
- 2026: 1 · 2025: 1 · 2022: 5
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuro-Ophthalmology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- The Medicine Forum (submittedVersion, cc-by-nc-nd)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- DZNE Pub (submittedVersion)
- Funders
- E-Rare
- National Institute for Health and Care Research (G1002570)
- Sight Research UK (SEE 003)
- Agence Nationale de la Recherche (ANR‐10‐LABX‐65, ANR18, 10-LABX-65, ANR-18-IAHU-0001, ANR-10)
- Bundesministerium für Bildung und Forschung (01GM1920B, 01GM1906A)
- Ministero della Salute (2018-, RF-2018-12366703, RF-2018)
- Isaac Newton Trust (G1002570)
- Moorfields Eye Hospital NHS Foundation Trust
- Moorfields Eye Charity
- National Institutes of Health (-0001, EY006360)
- Medical Research Council (G1002570)
- National Eye Institute (EY 006360, P30EY006360)
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- Leber's hereditary optic neuropathy, REVERSE trial, best-corrected visual acuity, contrast sensitivity, visual field, retinal nerve fiber layer thickness, disease progression, subacute phase
- MeSH terms
- Adolescent, Adult, Aged, Cross-Sectional Studies, DNA, Mitochondrial, Double-Blind Method, Female, Humans, Male, Middle Aged, Retinal Ganglion Cells, Visual Acuity, Visual Fields, Genetic Therapy, Optic Atrophy, Hereditary, Leber, Tomography, Optical Coherence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies. https://app.cochat.ai/papers/10.1097/wno.0000000000001316
- The paper
- Moster, M. L., Sergott, R. C., Newman, N. J., Yu-Wai-Man, P., Carelli, V., Bryan, M. S., Smits, G., Biousse, V., Vignal-Clermont, C., Klopstock, T., Sadun, A. A., DeBusk, A. A., Carbonelli, M., Hage, R., Priglinger, S., Karanjia, R., Blouin, L., Taiel, M., Katz, B., . . . for the LHON study group. (2021). Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies. Journal of Neuro-Ophthalmology. https://doi.org/10.1097/wno.0000000000001316
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.